Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas L Boggs

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
The Overdose Education and Naloxone Distribution Program at a VA HospitalAlyssa M Peckham, Douglas L Boggs
Neuroscience and Biobehavioral Reviews|November 10, 2009
The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literatureBernard A Fischer, Douglas L Boggs
The Psychiatric Clinics of North America|August 28, 2007
Reaching for wellness in schizophreniaDeanna L Kelly, Douglas L Boggs, Robert R Conley
Journal of Public Health Management and Practice : JPHMP|October 31, 2017
A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution ProgramAlyssa M Peckham, Maria E Niculete, Howard Steinberg, et al.
Comprehensive Psychiatry|April 20, 2010
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophreniaDeanna L Kelly, Stephanie Feldman, Douglas L Boggs, et al.
Schizophrenia Research|August 20, 2013
Pilot study of intravenous nicotine effects on cognitive performance in schizophreniaDouglas L Boggs, Mohini Ranganathan, R Andrew Sewell, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 7, 2017
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ<sup>9</sup>-TetrahydrocannabinolDouglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, et al.
Current Pharmaceutical Design|December 19, 2013
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophreniaDouglas L Boggs, Jon Carlson, Jose Cortes-Briones, et al.
The Psychiatric Quarterly|January 25, 2008
Comparison of clozapine response for inpatients in the research setting versus routine clinical practiceDouglas L Boggs, Deanna L Kelly, Raymond C Love, et al.
The Primary Care Companion for CNS Disorders|November 12, 2016
Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis WithdrawalMaju Mathew Koola, Deanna L Kelly, Robert P McMahon, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|February 16, 2019
The Overdose Education and Naloxone Distribution Program at a VA HospitalAlyssa M Peckham, Douglas L Boggs
Neuroscience and Biobehavioral Reviews|November 10, 2009
The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literatureBernard A Fischer, Douglas L Boggs
The Psychiatric Clinics of North America|August 28, 2007
Reaching for wellness in schizophreniaDeanna L Kelly, Douglas L Boggs, Robert R Conley
Journal of Public Health Management and Practice : JPHMP|October 31, 2017
A Survey of Prescribers' Attitudes, Knowledge, Comfort, and Fear of Consequences Related to an Opioid Overdose Education and Naloxone Distribution ProgramAlyssa M Peckham, Maria E Niculete, Howard Steinberg, et al.
Comprehensive Psychiatry|April 20, 2010
Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophreniaDeanna L Kelly, Stephanie Feldman, Douglas L Boggs, et al.
Schizophrenia Research|August 20, 2013
Pilot study of intravenous nicotine effects on cognitive performance in schizophreniaDouglas L Boggs, Mohini Ranganathan, R Andrew Sewell, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 7, 2017
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ<sup>9</sup>-TetrahydrocannabinolDouglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, et al.
Current Pharmaceutical Design|December 19, 2013
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophreniaDouglas L Boggs, Jon Carlson, Jose Cortes-Briones, et al.
The Psychiatric Quarterly|January 25, 2008
Comparison of clozapine response for inpatients in the research setting versus routine clinical practiceDouglas L Boggs, Deanna L Kelly, Raymond C Love, et al.
The Primary Care Companion for CNS Disorders|November 12, 2016
Psychoactive Substance Use by Adults With Schizophrenia Before and During Cannabis WithdrawalMaju Mathew Koola, Deanna L Kelly, Robert P McMahon, et al.
Pageof 3